These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24282277)

  • 1. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
    Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
    Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
    Cortés C; Kozma SC; Tauler A; Ambrosio S
    Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption.
    Watcharasit P; Thiantanawat A; Satayavivad J
    J Appl Toxicol; 2008 May; 28(4):466-74. PubMed ID: 17849503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Choi J
    PLoS One; 2013; 8(4):e60383. PubMed ID: 23565238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
    Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
    Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
    Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.